Trusted Resources: Education
Scientific literature and patient education texts
Nusinersen: A Review in 5q Spinal Muscular Atrophy
source: CNS drugs
year: 2021
authors: Hoy SM
summary/abstract:Survival motor neuron 1 (SMN1), located on chromosome 5q, encodes the survival motor neuron (SMN) protein. A deletion or mutation in SMN1 results in a rare neuromuscular disorder: 5q spinal muscular atrophy (SMA). In such patients, SMN protein production relies solely on SMN2. Nusinersen (Spinraza) is a modified antisense oligonucleotide approved for the treatment of 5q SMA. Administered intrathecally, it modifies SMN2 pre-messenger RNA splicing, thereby increasing full-length SMN protein levels. Interim analyses from an ongoing phase II study suggest substantial clinical benefits with nusinersen initiation in presymptomatic patients. In phase III studies, nusinersen achieved significant and/or clinically relevant improvements in motor function in symptomatic patients with infantile- and later-onset 5q SMA, and significantly improved event-free survival and overall survival in patients with infantile-onset 5q SMA. Longer term (up to a median of ≈ 6 years of available data), motor function was maintained or improved in symptomatic patients. Nusinersen had a favourable safety profile in clinical studies in presymptomatic and symptomatic patients. Real-world experience supports the effectiveness, safety and tolerability of nusinersen in symptomatic patients of all ages. Thus, nusinersen remains an important treatment option among a broad range of 5q SMA patients.
organization: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.DOI: 10.1007/s40263-021-00878-x
read more
Related Content
-
Spine Surgery Effective in SMA Type 1 Children, But Not Without RisksSurgery to correct kyphoscoliosis — a ...
-
Gene Therapy for SMA Type 1: Evelyn’s Storyhttps://www.youtube.com/watch?v=yRrqbvUv...
-
Safety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Carrier Screening for Genetic ConditionsCarrier screening is a term used to desc...
-
New Gene Therapy Transforms SMA (Spinal Muscular Atrophy)https://www.youtube.com/watch?v=C5Dl3iMv...